NeoGenomics, Inc.
NeoGenomics operates cancer-focused testing labs in US and UK. It offers various testing services to hospitals, academic centers, pathologists, and pharmaceutical companies. Services include cytogenetics, FISH, flow cytometry, immunohistochemistry, digital imaging, molecular testing, and morphologic analysis. The company also supports pharmaceutical clients oncology programs. Founded in 2001 and headquartered in Fort Myers, Florida.
Overview
Strengths
- Consistent growth: revenue has compounded at 10.4% a year over 5 years, rising every year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.4%) has been below its cost of capital of 9.8% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -30% to -3% over the last 6 years, with operating losses in 6 of them.
Key Financial Data